| 元智大學 |
2013-02 |
Treatment of waters and wastewaters containing sulfur dyes: A review
|
T.A. Nguyen; Juang R.-S. |
| 臺北醫學大學 |
2006 |
Treatment of Woman with Adenomyosis by Debulking Surgery and Subsequent Gonadotropin-Releasing Hormone Agonist Therapy Preserves the Potential of Fertility and Achieves Good Pregnancy Outcomes.
|
曾啟瑞; Chen PH; Wang IT; Chen CS; Tang WL; Liu WM; Tzeng CR |
| 中國醫藥大學 |
2007-11-18 |
Treatment option in surgical menopause
|
葉聯舜(Lian-Shung Yeh) |
| 臺大學術典藏 |
2020 |
Treatment options for COVID-19: The reality and challenges
|
PO-REN HSUEH; Jean S.-S.;Lee P.-I.;Po-Ren Hsueh; Jean S.-S.; Lee P.-I. |
| 臺大學術典藏 |
2021-01-07T06:08:38Z |
Treatment options for COVID-19: The reality and challenges
|
Jean S.-S.; PING-ING LEE; Hsueh P.-R.; Jean S.-S.;Ping-Ing Lee;Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-04T06:11:49Z |
Treatment options for dual HCV/HBV coinfection
|
Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:46Z |
Treatment options for dual HCV/HBV coinfection
|
CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-08-12T06:29:08Z |
Treatment options for primary breast cancer based on sophisticated philosophy - The importance of local controls
|
Huang C.-H.; KING-JEN CHANG |
| 臺大學術典藏 |
2021-03-11T07:58:24Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:29:29Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; JIN-YUAN SHIH; Yu C.-J. |
| 臺大學術典藏 |
2021-05-02T04:37:07Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; JANN-YUAN WANG; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T02:50:52Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T03:21:16Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-09-17T05:56:03Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; LI-TA KENG; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-10-04T07:15:37Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-11-29T05:55:31Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang, Sheng-Kai; Keng, Li-Ta; Chang, Chia-Hao; Wen, Yueh-Feng; Lee, Meng-Rui; CHING-YAO YANG; Wang, Jann-Yuan; Ko, Jen-Chung; Shih, Jin-Yuan; Yu, Chong-Jen |
| 臺大學術典藏 |
2021-05-02T03:29:21Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2021-02-02T09:21:39Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen, Yueh Feng; MENG-RUI LEE; Yang, Ching Yao; JANN-YUAN WANG; JEN-CHUNG KO; JIN-YUAN SHIH; CHONG-JEN YU |
| 臺大學術典藏 |
2021-02-08T08:05:08Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Jen-Chung Ko;Sheng-Kai Liang;Li-Ta Keng;Chia-Hao Chang;Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu; JEN-CHUNG KO; SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu |
| 臺大學術典藏 |
2022-06-27T06:59:38Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; Ko J.-C.; Shih J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2004 |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Hong R.-L.; Hsu S.-M.; Su I.-J.; Chen Y.-C.; Yao M.; Tang J.-L.; HWEI-FANG TIEN; Li C.-C. |
| 臺大學術典藏 |
2021-01-06T03:58:54Z |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.; Tien H.-F.; JIH-LUH TANG; Yao M.; Chen Y.-C.; Su I.-J.; Hsu S.-M.; Hong R.-L. |
| 臺大學術典藏 |
2021-05-26T09:08:15Z |
Treatment Outcome and Pattern of Failure in 77 Patients with Sinonasal Natural Killer/T-Cell or T-Cell Lymphoma
|
Li C.-C.; Tien H.-F.; Tang J.-L.; Yao M.; YAO-CHANG CHEN; Su I.-J.; Hsu S.-M.; Hong R.-L. |
